Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CDTX 
Cidara Therapeutics Inc (CDTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: CDTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -30.38% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 245.25M USD | Price to earnings Ratio - | 1Y Target Price 36.6 |
Price to earnings Ratio - | 1Y Target Price 36.6 | ||
Volume (30-day avg) 137154 | Beta 0.88 | 52 Weeks Range 10.00 - 28.42 | Updated Date 03/30/2025 |
52 Weeks Range 10.00 - 28.42 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -26.82 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-03-07 | When - | Estimate -3.6725 | Actual -5.38 |
Profitability
Profit Margin - | Operating Margin (TTM) -7154.43% |
Management Effectiveness
Return on Assets (TTM) -40.46% | Return on Equity (TTM) -219.59% |
Valuation
Trailing PE - | Forward PE 5.75 | Enterprise Value 58999641 | Price to Sales(TTM) 192.35 |
Enterprise Value 58999641 | Price to Sales(TTM) 192.35 | ||
Enterprise Value to Revenue 46.27 | Enterprise Value to EBITDA -1.64 | Shares Outstanding 10953500 | Shares Floating 4566839 |
Shares Outstanding 10953500 | Shares Floating 4566839 | ||
Percent Insiders 1.38 | Percent Institutions 69.43 |
Analyst Ratings
Rating 4.4 | Target Price 31.5 | Buy 3 | Strong Buy 2 |
Buy 3 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cidara Therapeutics Inc
Company Overview
History and Background
Cidara Therapeutics, founded in 2012, focuses on developing therapies for serious fungal and viral infections. The company has primarily focused on its novel antifungal compound, rezafungin, and antiviral programs. It has faced challenges in securing regulatory approvals and financing.
Core Business Areas
- Antifungal Therapeutics: Focuses on developing rezafungin, a novel echinocandin antifungal for the treatment and prevention of invasive fungal infections.
- Antiviral Therapeutics: Focuses on developing antiviral therapies with a focus on viral diseases. The antiviral program is less developed compared to antifungal program.
Leadership and Structure
The leadership team is headed by Jeffrey Stein, Ph.D. as the president and CEO. The organizational structure is typical of a small biotechnology company, with departments focusing on research and development, clinical operations, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Rezafungin: Rezafungin is Cidara's primary product, an echinocandin antifungal. While it has gained FDA approval, market penetration and revenue generation are still in early stages. Competitors include other echinocandin antifungals from companies like Merck (Cancidas, anidulafungin) and Astellas Pharma (Mycamine, micafungin), as well as azole antifungals.
Market Dynamics
Industry Overview
The antifungal market is driven by the increasing incidence of invasive fungal infections, particularly in immunocompromised patients. The antiviral market is seeing increasing interest, partially driven by global pandemics.
Positioning
Cidara is positioned as a specialty pharmaceutical company focused on addressing unmet needs in the treatment of fungal and viral infections. Its competitive advantage, if realized, lies in the unique properties of rezafungin, such as its potential for once-weekly administration.
Total Addressable Market (TAM)
The global antifungal market is estimated to be worth billions of dollars. Rezafungin aims to capture a portion of this market by addressing the unmet need for effective and convenient treatments for invasive fungal infections. The TAM for rezafungin is a subset of the overall antifungal market and estimated to be $500M+.
Upturn SWOT Analysis
Strengths
- Novel antifungal compound (rezafungin)
- FDA Approval for Rezafungin
- Experienced management team
Weaknesses
- Limited financial resources
- Reliance on a single key product (rezafungin)
- Lack of established commercial infrastructure
Opportunities
- Potential for strategic partnerships
- Expansion into new markets
- Development of additional antiviral therapies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent expiry
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- MRK
- PFE
- GILD
Competitive Landscape
Cidara faces intense competition from established pharmaceutical companies with greater resources and broader product portfolios. Its competitive advantage lies in the potential clinical benefits of rezafungin.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company being in the development stage, with no significant product revenue until recent FDA approval of Rezafungin.
Future Projections: Future growth depends on the successful commercialization of rezafungin and the development of its pipeline. Analyst estimates vary depending on the success of the commercialization.
Recent Initiatives: Recent strategic initiatives include securing FDA approval for rezafungin and establishing commercial partnerships.
Summary
Cidara Therapeutics is a high-risk, high-reward biotechnology company focused on infectious diseases. The recent FDA approval of rezafungin offers potential, but Cidara needs to successfully commercialize the drug in a competitive market. Financial challenges remain a significant hurdle for the company's long-term success. They need to secure further funding or revenue streams to remain viable and competitive.
Similar Companies
- MRK
- PFE
- GILD
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Press releases
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share figures are estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cidara Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2015-04-15 | President, CEO & Executive Director Dr. Jeffrey L. Stein Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 38 | Website https://www.cidara.com |
Full time employees 38 | Website https://www.cidara.com | ||
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.